BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 23 2024
0mins
Should l Buy ?
Source: Newsfilter
Bright Green Corporation's Supply Agreement: Bright Green Corporation has signed a letter of intent to supply DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, aiming to produce pharmaceutical-grade Active Pharmaceutical Ingredients (APIs) in compliance with regulatory standards.
Future Prospects: The agreement positions Bright Green as a leading domestic supplier of controlled plant-based raw materials for cannabinoid, psychedelic, and opioid drugs, with plans for further fundraising and supply agreements to enhance its market presence in 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
